DCGI nod to Bajaj Healthcare for manufacturing Parkinson's disease psychosis drug Pimavanserin in India
Mumbai: Bajaj Healthcare Limited has announced that it has received approval from the Drug Controller General of India (DCGI) to manufacture both the API and Drug Formulation of Pimavanserin, a 34 mg capsule.
Pimavanserin is an atypical antipsychotic used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
Pimavanserin, marketed globally as NUPLAZID, has become a preferred treatment in the US antipsychotic segment. In a recent update, Acadia Pharmaceuticals announced that NUPLAZID, along with its other brand DAYBUE, is projected to generate more than $1 billion in net sales in 2025. The company has also extended offer for manufacturing of Pimavanserin to several leading Indian pharmaceutical companies, ensuring the product’s availability in the domestic market.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.